Robot suit aims to keep ALS patients walking longer
NCT ID NCT06199284
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a robotic exoskeleton called Atalante can safely help people with ALS maintain their ability to walk. The idea is that the suit provides natural leg movements and feedback to the brain, which may slow down walking decline. About 20 adults with slow-progressing ALS will try the device in a supervised setting. The main goal is to check safety, but researchers will also measure walking speed, balance, and breathing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2024
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with amyotrophic lateral sclerosis (defined according to the El Escorial criteria: possible, probable or definite), at the time of diagnosis * Male or female, between 18 and 70 years of age * Slowly and moderately evolving patients ∆ ALS Progression rate (FS) ≤ 1.11 (The ALS progression rate was calculated as follows: (48 - ALSFRS-R at screening visit) / (duration from onset to this visit (month)) (Kimura et al., 2006). ALSFRS-R progression will be classified as slow (∆FS ≤ 0.47), intermediate (0.47 ≤ ∆PR ≤1.11) or fast (∆PR \> 1.11) (Labra et al., 2016). * Manual muscle testing ≥ 3 for deltoid muscle and ≥ 4 for neck flexors and extensors muscles * Ambulatory status: a stable gait deficit with a total score between 3 and 6 on the ALSFRS-R sub-items "walking" and "climbing stairs" * French speaking patient * Patient affiliated with the French social security system * Signed informed consent * Measurements related to the use of the Atalante exoskeleton: * Height between 155 and 190 cm * Weight \< 90 kg * Pelvis width \< 46 cm in seated position * Thigh length between 56.8 and 64.8 cm * Leg length \> 45.7cm or less than: * 60.7cm if ankle dorsi flexion is ≥16° * 57.7cm if ankle dorsi flexion is ≥13°and \<16° * 56.7cm if ankle dorsi flexion is\>10°and ≤13° * 55.7cm if ankle dorsi flexion is ≥ 0°and ≤10° * Joint amplitudes of lower limbs : * Hip: flexion 90°, extension 5°, medial rotation 10°, lateral rotation 20°, abduction 17°, adduction 10° * Knee: flexion 5-110° * Ankle: dorsiflexion (knee straight) 0°, plantarflexion 9°, eversion18°, inversion 18°. Exclusion Criteria: * Osteoporosis at the femoral and/or lumbar level (T score ≤ -2.5), confirmed by bone densitometry at both the femoral and lumbar sites. * Pressure ulcers in areas of contact with the exoskeleton * Severe spasticity (greater than Ashworth 3) for adductor, hamstring, quadriceps and sural triceps muscles or uncontrolled clonus * Cardiac or respiratory contraindications to physical effort * Cognitive impairment that can affect comprehension * Pregnancy or attempted pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (amyotrophic lateral sclerosis) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
Institut de myologie
Paris, 75013, France
-
Station Debout
Paris, 75001, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood bank unlock the genetics of brain disease?
- Blood markers may unlock early ALS detection — a study puts them to the test
- Brain implant aims to give voice to those trapped in silence
- Nasal spray aims to tame brain inflammation in ALS
- Robotic arm could help people with paralysis regain independence at home
- Experimental cell therapy tested in 3 ALS patients